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ABSTRACT: The Aβ5−x peptides (x = 38, 40, 42) are minor Aβ species in normal
brains but elevated upon the application of inhibitors of Aβ processing enzymes.
They are interesting from the point of view of coordination chemistry for the
presence of an Arg-His metal binding sequence at their N-terminus capable of
forming a 3-nitrogen (3N) three-coordinate chelate system. Similar sequences in
other bioactive peptides were shown to bind Cu(II) ions in biological systems.
Therefore, we investigated Cu(II) complex formation and reactivity of a series of
truncated Aβ5−x peptide models comprising the metal binding site: Aβ5−9, Aβ5−12,
Aβ5−12Y10F, and Aβ5−16. Using CD and UV−vis spectroscopies and
potentiometry, we found that all peptides coordinated the Cu(II) ion with
substantial affinities higher than 3 × 1012 M−1 at pH 7.4 for Aβ5−9 and Aβ5−12. This
affinity was elevated 3-fold in Aβ5−16 by the formation of the internal macrochelate
with the fourth coordination site occupied by the imidazole nitrogen of the His13 or His14 residue. A much higher boost of affinity
could be achieved in Aβ5−9 and Aβ5−12 by adding appropriate amounts of the external imidazole ligand. The 3N Cu-Aβ5−x complexes
could be irreversibly reduced to Cu(I) at about −0.6 V vs Ag/AgCl and oxidized to Cu(III) at about 1.2 V vs Ag/AgCl. The internal
or external imidazole coordination to the 3N core resulted in a slight destabilization of the Cu(I) state and stabilization of the
Cu(III) state. Taken together these results indicate that Aβ5−x peptides, which bind Cu(II) ions much more strongly than Aβ1−x
peptides and only slightly weaker than Aβ4−x peptides could interfere with Cu(II) handling by these peptides, adding to copper
dyshomeostasis in Alzheimer brains.
■ INTRODUCTION
Alzheimer’s disease (AD) accounts for approximately 50−70%
cases of dementia, over 50 million people worldwide.1,2
Amyloid-β (Aβ) peptides are at the center of AD pathology.
They compose amyloid plaques, a historic hallmark of the
disease, and were more recently demonstrated to form
neurotoxic oligomers.3,4 Aβ peptides are derived from the
amyloid precursor protein (APP), which undergoes alternative
proteolytic cleavage pathways in amyloidogenic and non-
amyloidogenic processes. In the amyloidogenic pathway APP is
cleaved by β-secretase (BACE1), a membrane-anchored
aspartyl protease which cleaves APP before position 1 of the
Aβ domain, and γ-secretase, a membrane-bound protease
complex responsible for creation of the Aβ C-terminus.5 The
Aβ1−40 and Aβ1−42 peptides formed in this pathway are further
processed hydrolytically to N-terminally truncated species,
which represent more than 60% of all Aβ species in AD brains.
Aβ4−42 is the most abundant of these peptides.
6−9 Another is
Aβ5−42, detected in Aβ deposits in brains of sporadic and
familial AD victims and in transgenic mouse models.9−11
The origin of Aβ5−x species (x = 38, 40, 42) is unclear. They
were shown to be elevated in the course of application of
inhibitors of BACE1 in experimental animals.5,12 This suggests
direct alternative cleavage of APP, becoming possible when the
main pathway is inhibited. They can also be produced by
caspases, largely cellular apoptotic proteases implicated in AD
neurodegeneration.13
Aβ5−x peptides contain His in the second position (Xaa-
His). Such Xaa-His arrangement creates a specific Cu(II)
binding site distinct from both the dynamic ensemble of
macrochelate species of Aβ1−x peptides
14,15 and the rigid
ATCUN/NTS chelate system of Aβ4−x peptides.
16−18 The
basic structure of Xaa-His-Zaa cupric complexes, derived from
X-ray studies of Gly-His-Lys (GHK) and spectroscopic studies
of many oligopeptides bearing various Xaa substitutions is
three-coordinate, with the Xaa N-terminus, the Xaa-His
peptide bond, and the His imidazole providing three nitrogen
ligands arranged in a square-planar fashion around the Cu(II)
ion (3N species). The fourth position can be occupied by a
Received: June 15, 2020
Published: September 14, 2020
Articlepubs.acs.org/IC
© 2020 American Chemical Society
14000
https://dx.doi.org/10.1021/acs.inorgchem.0c01773
Inorg. Chem. 2020, 59, 14000−14011
This is an open access article published under a Creative Commons Attribution (CC-BY)
License, which permits unrestricted use, distribution and reproduction in any medium,



















































































water molecule or other ligands, such as imidazoles or
carboxylates from other peptide molecules, phosphate ions,
etc.19−21 The amino acid residue directly following His (Zaa in
Xaa-His-Zaa... sequences) cannot participate in the coordina-
tion for sterical reasons. The stability constants available in the
literature indicate that the effective stability constants of
Cu(II) complexes of Xaa-His-Zaa peptides are in the range of
1012−1013 M−1, slightly less than those of ATCUN/NTS
motifs.18,21−23 We demonstrated, however, that at a sufficiently
high concentration of the ternary ligand the effective stability
constants of such a ternary XHZ-Cu(II)-L complex may be
elevated by one or 2 orders of magnitude.20
In this work, we aimed to characterize Cu(II) coordination
and electrochemical properties of resulting complexes, Aβ5−x
peptides, by using Aβ5−16 as a suitable well-soluble model,
analogously to Aβ1−16 and Aβ4−16 model peptides.
15,16 Because
of the presence of two metal binding regions in this peptide,
one at the N-terminus and another at the His13-His14 couple,
we also used shorter peptides, Aβ5−9 and Aβ5−12 as simplified
models. For a better understanding of the role of Tyr10 in the
studied processes, we also used a modified Aβ5−12Y10F
(Aβ5−12F) peptide in some experiments (see Scheme 1 for
sequences). Spectroscopic (UV−vis, CD, fluorescence) and
potentiometric experiments were used to decipher and
quantify the set of complex species formed in a broad pH
range, while their redox properties were investigated using
voltammetry (CV and DPV). Then, spectroscopic and
electrochemical titrations of Cu(II)-Aβ5−x complexes with
imidazole, a model of His residues in proteins, were employed
to estimate the influence of such interactions on the stability
and reactivity of studied complexes. The obtained quantitative
description allowed us to assess the potential role of Aβ5−x
peptides in copper physiology in the brain.
■ EXPERIMENTAL METHODS
Materials. N-α-9-Fluorenylmethyloxycarbonyl (Fmoc) amino
acids were purchased from Novabiochem. Trifluoroacetic acid
(TFA), piperidine, and N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-
1-yl)uronium hexafluorophosphate (HBTU) were obtained from
Merck. Triisopropylsilane (TIS), N,N-diisopropylethylamine (DIEA),
4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), CuCl2,
Cu(NO3)2·H2O, NaOH, KOH, HCl, KNO3, HNO3, and imidazole
were from Sigma. The TentaGel S RAM resin was purchased from
RAPP Polymere. Diethyl ether and dichloromethane (DCM) were
from Chempur. Acetonitrile and calibrated 0.1 M NaOH solution for
potentiometry were from POCH, and dimethylformamide (DMF)
was from Roth.
Peptide Synthesis. Aβ5−16(RHDSGYEVHHQK-NH2),
Aβ5−12(RHDSGYEV-NH2), Aβ5−9(RHDSG-NH2), and Aβ5−12F
(RHDSGFEV-NH2) were synthesized by solid-phase peptide syn-
thesis using a CEM Liberty microwave peptide synthesizer (Applied
Biosystems) according to a Fmoc/tBu protocol with HBTU and
DIEA as coupling reagents and 20% piperidine in DMF as a Fmoc
removal agent.24 TentaGel S RAM resin was used as a solid phase.
The peptides were cleaved from the resin in TFA/TIS/water
95:2.5:2.5 v/v/v for 2 h. Then, the peptides were precipitated with
cold diethyl ether, centrifugated, dissolved in water, and lyophilized.
The crude peptides were purified by HPLC (Waters) following a
detection at 220 nm/280 nm using a mix of eluting solvents A (0.1%
(v/v) TFA in water) and B (0.1% (v/v) TFA in 90% (v/v)
acetonitrile). The purification method was a gradient of eluents 5−
45% of B within 40 min, flow 2 mL/min. The mass of the pure
peptides was further verified by ESI-MS. The concentrations of initial
peptide stock solutions were determined by potentiometric titrations.
Concentrations of secondary and subsequent stock solutions of
Aβ5−12 and Aβ5−16 were determined using an extinction coefficient ε
of 1375 M−1 cm−1 at 275 nm. For Aβ5−12F and Aβ5−9 ε values of 200
M−1 cm−1 at 258 nm and ε of 9032 M−1 cm−1 at 214 nm were used.25
UV−vis, CD, and Fluorescence Spectroscopy. The UV−vis
spectra were obtained on a PerkinElmer spectrophotometer over the
spectral range of 200−900 nm. The circular dichroism (CD) spectra
were recorded over the range of 250−800 nm on a Jasco 815
spectropolarimeter. All spectroscopic measurements were performed
at 25 °C in a 1 cm path length quartz cuvette.
Titrations with NaOH (pH dependence): Samples containing 1 mM
Aβ (Aβ5−9, Aβ5−12, Aβ5−12F, Aβ5−16), and 0.9 mM Cu(II) or 1 mM Aβ
(Aβ5−16) and 1.8 mM Cu(II) were titrated with a small portion of
concentrated NaOH in the pH range 2.5−10.
Titrations with imidazole/Aβ5−9/Aβ1−16: Samples containing 1 mM
Aβ (Aβ5−9, Aβ5−12, Aβ5−12F, Aβ5−16) and 0.8 mM Cu(II) at pH 7.4
were titrated with a small portion of imidazole/Aβ5−9/Aβ1−16 stock
solution. The pH of the sample was strictly controlled during the
experiment and adjusted if necessary.
Kinetic Experiment. Aβ4−9 was added to the sample containing 0.9
mM Cu(II) and 1 mM Aβ5−9 in 20 mM HEPES pH 7.4 to the final
Aβ4−9 concentration of 1 mM. The changes in UV−vis spectra were
monitored for 24 h.
Fluorescence spectra were registered using a Cary Eclipse
spectrofluorimeter (Varian) with the excitation wavelength of 275
nm and detection of emission in the range of 280−400 nm. All
fluorescence measurements were performed at 25 °C in a 1 cm path
length quartz cuvette. The samples of 20 μM Aβ5−12 or 20 μM
Aβ5−12/19 μM CuCl2 were titrated with NaOH from pH 4.2 to 12.2.
The pK values were calculated using Hill equations eq 1 and eq 2:
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where F stands for spectroscopic intensity at given pH; p1 and p2
stand for spectroscopic intensity for the fully protonated or
deprotonated state, respectively; px stands for the spectroscopic
intensity of the first step in the two-step process; and n, n1, and n2
stand for Hill coefficients.
Potentiometry. Potentiometric titrations were performed on a
Titrando 907 automatic titrator (Metrohm) using a combined glass-
Ag/AgCl electrode (InLabMicro, Mettler Toledo, Switzerland). The
electrode was calibrated daily by titrating nitric acid.26 The CO2-free
solution of 0.1 M NaOH was used as the titrant. All experiments were
performed under argon at 25 °C. Sample volumes were 1.5 mL. The
samples contained 1.0 mM Aβ peptide (Aβ5−16, Aβ5−12, Aβ5−9)
dissolved in 4 mM HNO3/96 mM KNO3. The Cu(II) complex
formation was studied for the different peptide:metal stoichiometries
(1:2, 1:1, 1:0.5) using a 5−10% excess of peptides over metal ions,
over the pH range from 2.3 to 12.2. SUPERQUAD and HYPER-
QUAD were used to analyze the data.27,28 At least three titrations
Scheme 1. Sequences of Aβ5−x Peptides Studied in This
Worka
aResidues whose side chains contribute to Cu(II) binding are
highlighted in red (His) and blue (Tyr).
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were performed separately to determined the protonation and Cu(II)
stability constants of the studied compounds.
Voltammetry. The electrochemical experiments were done in a
three-electrode arrangement with Ag/AgCl as the reference, platinum
wire as the counter, and glassy carbon electrode (GCE, BASi, 3 mm
diameter) as the working electrode. The reference electrode was
separated from the working solution by an electrolytic bridge filled
with 4 mM HNO3/96 mM KNO3 solution. The GC electrode was
sequentially mechanically polished with 1.0 and 0.3 μm alumina
powder on a Buehler polishing cloth to a mirror-like surface. In order
to remove the remaining powder, the electrode was sonicated for 1
min in deionized water. All electrochemical measurements were
carried out in 96 mM KNO3 solutions containing 4 mM HNO3
solution at pH 7.4. The pH was adjusted by adding small volumes of
concentrated KOH or HNO3 solutions; the concentrations of
peptides were 0.5 mM and the ligand-to-Cu(II) ratio was 1:0.8 in
all cases (a small Cu(II) deficiency was applied to avoid the
interference from uncomplexed Cu(II) cations). In ternary complex
investigations imidazole was added to the Cu(II)−peptide complex
up to 10 mM concentration. The pH was closely controlled before,
during, and at the end of each voltammetric measurement. Oxygen
was removed from the sample solution by passing argon for 5−10 min
before all measurements, and an argon blanket was maintained over
the solution during the experiments carried out at 25 °C.
Cyclic (CV) and differential pulse voltammetry (DPV) experi-
ments were performed using the CHI 1030 potentiostat (CH
Instrument, Austin, USA). For all presented CV curves, the scan rate
(v) was 100 mV/s. The following parameters were used in DPV: pulse
amplitude 50 mV, pulse time 100 ms.
■ RESULTS AND DISCUSSION
Aβ5−9 Complexes. We first performed a set of pH-metric
titrations of the studied peptides in the absence and presence
of Cu(II) ions. The protonation constants calculated from
these experiments are presented in Table 1. The assignments
of proton exchanging groups mainly contributing to given
protonation constants are based on previous studies of
analogous peptides.16,29,30 The pKa values are typical for the
respective groups and sufficiently well separated to make these
assignments unambiguous.31
The potentiometric titrations performed at various Cu(II)/
peptide ratios for Aβ5−9 indicated the formation of complexes
having solely a 1:1 copper-to-peptide stoichiometry and
differing by the number of bound/released hydrogen ions
(Table 2). The CD and UV−vis spectra of Cu(II)-Aβ5−9
complexes are presented in Figures 1 and S1, respectively.
Figure 2 demonstrates the potentiometric species distribution
compared to parameters derived from these spectra. The
quantitative agreement of these results allowed us to calculate
the spectroscopic parameters for individual complexes, as given
in Table 3. The first complex formed is a 3N species with
spectroscopic parameters analogous to those recorded earlier
for GHK, WHWSKNR-NH2, and GHTD-NH2 peptides,
19−23
with the fourth equatorial site occupied by a water molecule. It
Table 1. Protonation Constants (log βa and pKa Values) of
Aβ5−9, Aβ5−12, and Aβ5−16 (L) at I = 0.1 M (KNO3),
Determined by Potentiometry at 25 °Cb16,29,30
Species Log βa pKa Assignment
Aβ5−9
HL 7.37(1) 7.37 Arg5 N-term.
H2L 13.51(1) 6.13 His6
H3L 16.67(1) 3.17 Asp7
Aβ5−12
HL 10.08(1) 10.08 Tyr10
H2L 17.60(1) 7.52 Arg5 N-term.
H3L 23.84(1) 6.25 His6
H4L 28.21(1) 4.37 Glu11
H5L 30.94(1) 2.73 Asp7
Aβ5−16
HL 10.39(1) 10.39 Tyr10/Lys16
H2L 20.35(1) 9.96
H3L 27.94(1) 7.60 Arg5 N-term.
H4L 34.61(1) 6.67 His6/13/14
H5L 40.92(1) 6.31
H6L 46.43(1) 5.50
H7L 50.35(1) 3.92 Glu11
H8L 52.83(1) 2.48 Asp7
aβ(HnL) = [HnL]/([L][H
+])n.
bStandard deviations on the last digits
provided by HYPERQUAD,28 given in parentheses, represent
statistical errors of constant determinations. Assignments are based
on literature values.
Table 2. Stability Constants (log βa and pKa Values) of
Cu(II) Complexes of Aβ5−9, Aβ5−12, and Aβ5−16 (L) at I =
0.1 M (KNO3), Determined by Potentiometry at 25 °C
b





CuH−1L 5.66(1) 3.82 Asp7 3N+H2O






CuHL 20.44(1) 3.23 Asp7 3N+H2O
CuL 15.76(1) 4.69 Glu11 3N+H2O
CuH−1L 6.29(2) 9.47 Tyr10/H2O 3N/Tyr10 and
3N+OH−






CuH4L 42.79(1) 3.212 Asp7 3N+H2O
CuH3L 38.62(1) 4.169 Glu11 3N+H2O
CuH2L 33.46(1) 5.159 His13/14 3N+N
CuHL 26.11(2) 7.35 His13/14 3N+N







Cu2L 25.37(1) 6.134 His13/14 N
− 3N+H2O + 2N
Cu2H−1L 19.08(1) 6.29 3N+H2O + 3N
Cu2H−2L 10.15(1) 8.93 Val12/Glu11 N
− 3N+H2O + 4N
Cu2H−3L 1.05(1) 9.1 Equatorial H2O 3N/OH- + 4N
Cu2H−4L −9.4(1) 10.45 Lys16/Tyr10 3N/OH- + 4N







the last digits provided by HYPERQUAD,28 given in parentheses,
represent statistical errors of constant determinations. Assignments
are based on literature values.20,21,29,30 Coordination modes are
derived from the analysis presented below.
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contains two spectroscopic forms, CuL and CuH−1L, differing
by deprotonation of the Asp7 side chain carboxyl function.
This event, recorded by potentiometry with the pKa of 3.82,
does not affect the spectroscopic parameters (Tables 2 and 3).
It is not surprising, as the coordination of the Asp7 carboxylate
to the Cu(II) ion bound in the 3N core provided by Arg5 and
His6 is excluded by the complete geometry. The elevation of
Asp7 pKa by 0.65 pH units can be explained by lowering the
overall molecular charge by Cu(II) coordination by one,
compared to the unbound peptide.
The next recorded deprotonation occurred with the pKa of
9.35 and was associated by a significant blue shift of the d−d
band maximum, the change of its symmetry in CD, and
concomitant alterations in charge transfer bands (Figure 1,
Table 3). These changes are due to the deprotonation of the
coordinated water molecule.20,21 The additional split in the d−
d band, not observed in titrations of WHWSKNR-NH2 and
GHTD-NH2 complexes,
19,20 is indicative of an additional
interaction involving the coordinated hydroxyl anion, most
likely with the cationic Arg side chain.
At still higher pH above 10 a further set of changes appeared
in the CD spectra, with a characteristic strong negative feature
at 500 nm. According to the literature, they are due to the
replacement of the hydroxyl group by the deprotonated Nτ of
the imidazole ring, possibly resulting in imidazole-bridged
oligomers.21,32,33
The potentiometric titrations did not provide evidence for
the presence of a CuL2-type complex. Such complexes were
reported previously for simpler XHZ peptides by potentiom-
etry, but with little support by independent direct techniques
in solution.17,19,23,32−35 No such complex was detected for
WHWSKNR-NH2. It was also invisible for potentiometry in
the study of GHTD-NH2 complexes, due to insufficient
stability at submillimolar peptide concentrations, but a
spectroscopic titration with the peptide excess demonstrated
its existence at pH 7.4.21 Here we used the same approach to
detect it, as shown in Figure 3. The associated spectral changes
were very similar to those observed for GHTD-NH2, indicating
the formation of a 3 + 1N complex, with the water molecule
replaced by an imidazole nitrogen of the second peptide
molecule. The conditional stability constant derived from this
titration is provided in Table 4, and the spectral parameters of
Figure 1. pH dependence of CD spectra recorded at 25 °C for 0.9
mM Cu(II) and 1.0 mM Aβ5−9, at pH values color coded on the
graphs.
Figure 2. Species distribution calculated for 0.9 mM Cu(II) and 1.0
mM Aβ5−9, on the basis of constants presented in Tables 1 and 2, with
selected spectroscopic parameters overlaid.
Table 3. Spectroscopic Parameters for Cu(II) Mono-
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ad−d transition. bNim−CuII charge transfer (CT). cN−−CuII CT.
dNam−CuII CT. eTyr O−−CuII CT.
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this complex are given in Table 5, along with the parameters of
ternary complexes with imidazole.
Aβ5−12 and Aβ5−12F Complexes. The extension of the
sequence by residues 10−12, YEV, added two proton-
exchanging side chains, Tyr10 and Glu11 in Aβ5−12. Their
characteristic pKa values about 10 and 4, respectively, together
with the data for Aβ5−9, allowed us to directly assign the
respective protonation events to individual groups, as provided
in Table 1 and presented in Figure 4.
Accordingly, the lowest-pH complex of Aβ5−12 has the
CuH2L stoichiometry, but the same 3N coordination as the
CuL complex of Aβ5−9, as seen in CD and UV−vis spectra,
presented in Figures 5A and S2, respectively. The next two
deprotonations under pH 5 did not affect the spectra and can
be assigned to Asp7 and Glu11 carboxyl deprotonations. The
spectra became more complicated above pH 8, where two
overlapping deprotonations took place. In order to facilitate
the analysis, we performed spectroscopic titrations of Cu(II)-
Aβ5−12F, the analog having Tyr replaced with Phe. The
respective CD and UV−vis results are presented in Figures 5B
and S3.
The pKa values for the 3N complex formation obtained from
CD titrations were 3.77(1) and 3.51(2) for the formation of
3N complexes of Aβ5−12 and Aβ5−12F, respectively. The former
value is in a good agreement with the potentiometry-derived
value of 3.66. Based on the characteristic CT band at 400 nm,
seen particularly clearly in UV−vis spectra of Cu(II)-Aβ5−12
contrasted with Cu(II)-Aβ5−12F in the pH range 7−10 (Figure
6A) and CD titrations monitored at 370−380 nm (Figure 6B),
Figure 3. Top: the titration of 0.8 mM Cu(II) and 1.0 mM Aβ5−9 at
25 °C and pH 7.4 with the excess of Aβ5−9, up to 15 mM, monitored
by CD. Arrows mark the direction of changes. Bottom: the fit of the
conditional stability constant of the CuL2 complex at spectral areas of
maximum change: 635 nm (gray), 535 nm (green), and 315 nm
(orange).
Table 4. Conditional Stability Constants (M−1) for Binary
(CK7.4) and Ternary (
TK7.4) for Cu(II) Complexes of Aβ5−x
Peptides at pH 7.4a
TK7.4
Peptide CK7.4 imidazole Aβ5−9 Aβ1−16
Aβ5−9 5.75 × 1012 870 ± 69 283 ± 50 5200 ± 200
Aβ5−12 5.13 × 1012 557 ± 36 n.a. n.a.
Aβ5−16 9.55 × 1012 98 ± 27 n.a. n.a.
aCK7.4 values were calculated from potentiometric data using the CI
approach. Competitivity index (CI) was calculated for Cu(II),
peptide, and ligand (Z) concentrations of 0.001 M. CI is the value
of log KCuZ such as the condition∑ijk([CuiHjLk]) = [CuZ] is fulfilled,
where Z is a theoretical competitor.39 n. a. stands for not analyzed.
TK7.4 were calculated directly from spectroscopic titrations using eq 1.
Table 5. Spectroscopic Parameters of Ternary Complexes of












































ad−d transition. bNim−CuII charge transfer (CT). cN−−CuII CT.
dNam−CuII CT.
Figure 4. Species distribution calculated for 0.9 mM Cu(II) and 1.0
mM Aβ5−12, on the basis of constants presented in Tables 1 and 2,
with selected spectroscopic parameters of Aβ5−12 overlaid.
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we can assign the deprotonation event about pH 9 (8.89(3)
from CD, 8.95(7) from UV−vis) to deprotonation and
equatorial Cu(II) coordination of Tyr10 phenolate oxygen.36,37
This band disappears gradually above pH 9.5, in accord with
another deprotonation, which can thus be assigned to the
replacement of Tyr O− by the solution-derived OH− group,
with pKa = 9.92(5). At very high pH an imidazole bridged
species is formed as in Cu(II)-Aβ5−9.
The comparison of pKa values for uncoordinated Tyr, 10.08,
coordinated Tyr, 8.89, and deprotonated water in Cu(II)-
Aβ5−12, 9.92 vs 9.3 for Cu(II)-Aβ5−9 (average of potentio-
metric and spectroscopy calculations) and 9.62(3) in Aβ5−12F
(from spectroscopy), allowed us to estimate the ratio of Cu(II)
affinities of Tyr phenolate vs the hydroxyl group at pH 9 as ca.
8.3. The physiological relevance of this interaction is limited,
however, as the Cu(II) occupancy by Tyr phenolate at pH 7.4
is 3% or less, estimated from potentiometric data compared to
fluorescence titrations of Aβ5−12 and Cu(II)-Aβ5−12 (Figure
S4).
Aβ5−16 Complexes. A further C-terminal peptide sequence
extension by residues 13−16, VHHQK, added three proton-
exchanging side chains, compared to Aβ5−12, His13, His14, and
Lys16. As a result, the separation of contributions to
potentiometric macroconstants of Tyr10 and Lys16 on one
hand and of His6, His13, and His14 on another was not
possible, due to overlapping protonation processes. The
differences between the respective pKa values, presented in
Table 1, are close to statistical values for two and three
equivalent groups, 0.6 and 0.48 pH units, respectively.31 All
these values remain in their typical ranges.
Due to the presence of two distinct Cu(II) binding sites in
Aβ5−16, the spectroscopic and potentiometric experiments were
performed at the 1.8:1 Cu(II):peptide ratio, in addition to the
0.9:1 ratio used for shorter analogs. The CD titration for the
0.9:1 ratio is presented in Figure 7, the UV−vis titration in
Figure S5, and the species distribution plots in Figure 8. The
respective data for the 1.8:1 ratio are presented in Figures S6,
S7, and S8.
Figure 5. CD spectra recorded at 25 °C for 0.9 mM Cu(II) and 1.0
mM Aβ5−12 (A) or 0.9 mM Cu(II) and 1.0 mM Aβ5−12F (B) at pH
values color coded on the graphs.
Figure 6. (A) Comparison of UV−vis spectra of Cu(II) complexes of
spectra recorded at 25 °C for 0.9 mM Cu(II) and 1.0 mM Aβ5−12F
(solid lines) or Aβ5−12 (dotted lines) at pH values indicated on the
graph. (B) pH dependence of CD signals at 370−380 nm (red circles)
or 635−655 nm (black squares) derived from CD spectra shown in
Figure 5 for 0.9 mM Cu(II) and 1.0 mM Aβ5−12F (full symbols) or
Aβ5−12 (open symbols).
Figure 7. PH dependence of CD spectra recorded at 25 °C for 0.9
mM Cu(II) and 1.0 mM Aβ5−16, at pH values color coded on the
graph.
Figure 8. Species distribution calculated for 0.9 mM Cu(II) and 1.0
mM Aβ5−16, on the basis of constants presented in Tables 1 and 2,
with selected spectroscopic parameters of Aβ5−16 overlaid.
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At the 0.9:1 ratio the CuH5L and CuH4L and CuH3L
complexes present at low pH correspond to the 3N complex.
Its spectroscopic parameters with d−d bands at 600 nm at the
UV−vis spectrum as well as at 506 and 605 nm at the CD
spectrum are very similar to those observed for the 3N
complexes of Aβ5−9 and Aβ5−12. The pKa of formation of this
complex calculated from spectroscopic and potentiometric
data is 3.4−3.6. This spectroscopic species is superseded with
another, comprising the CuH2L and CuHL stoichiometries,
which exhibited a 35 nm blue shift of the d−d band in the
UV−vis spectra and significant changes in the CD pattern (see
Table 3, Figure 7, and Figure S5). The pKa of this process
derived from spectroscopy is 5.55. The only residues that can
release a proton in this pH range are His13 and His14. These
residues are essentially equivalent in the apopeptide, but their
pKa values in the complex are 5.16 and 7.35. These features
clearly indicate that His13 or His14 replaces the water
molecule in the fourth equatorial coordination site. This
observation is further supported by the lack of Tyr phenolate
coordination (the absence of a 400 nm band) above pH 8 in
Cu(II)-Aβ5−16. As a result the Cu(II)-independent Tyr10 and
Lys16 deprotonations occur at pH 9.5−10, along with the
third proton release, which must originate from the
replacement of Nim by OH− in the fourth site. This
replacement induces a small change in CD spectra as shown
in Figure 8, indicating that the pKa for this process is ca. 9.65,
about 0.3 log units higher than in Cu(II)-Aβ5−9. As for all
other Aβ5−x peptides a major spectral change above pH 11 was
noted, tentatively assigned to the formation of the imidazole
bridged tetramer. The protonic equivalence of His13 and
His14 and their similar distancing to the N-terminally
coordinated Cu(II) ion suggests that the 3 + 1N complex is
actually a mixture of His13 and His14 coordinated species,
perhaps with a slight distance-wise preference for His13.
The experiments performed at the Cu(II) excess indicate
that the 3N complex is formed in a fashion similar to that at
the 1:1 ratio, but it is followed by the additive formation of a
novel spectral band (∼579 nm) with the pKa of 5.90. This
complex is analogous to that observed before for Cu(II)-
Aβ4−16 and corresponds to an independent formation of the
second Cu(II) ion at the His13 and His14 residues.16 As
expected, the binding of the second Cu(II) ion at His13/His14
prevented the entry of His13/His14 Nim to the coordination
sphere of the N-terminal 3N complex.
Ternary Complexes. To further investigate the role of the
fourth equatorial site in Cu(II) coordination of Aβ5−x peptides,
we performed CD titrations of Cu(II)-Aβ5−9/Aβ5−12/Aβ5−16
complexes with imidazole (Im). The respective CD spectra
and titration curves are provided in Figure 9.
The addition of Im resulted in a blue-shift of d-d bands of
Cu(II)-Aβ5−9/Aβ5−12 from 600 to 550 nm as shown in Figure
9A and 9B, respectively. These changes were accompanied by a
10 nm blue-shift and an increase of intensity of CT bands at
340 and 300 nm. No changes in the d−d bands and only a
slight effect in CT signals were noticed during the analogous
titration of Cu(II)-Aβ5−16 (see Figure 9C), even at the final
250-fold excess of Im over Cu(II).
The effects seen for Cu(II)-Aβ5−9/Aβ5−12 complexes were
analogous to those seen previously for Im titrations of all Xaa-
His peptides studied by us recently, including WHWSKNR-
NH2, GHTD-NH2, and GHK
20,21,38 and are consistent with
the replacement of the equatorially coordinated water
molecule in the3N coordination mode (Nam, Nim, N−)
dominant at pH 7.4, with the Im nitrogen, forming the ternary
Figure 9. CD titrations and resulting titration curves for Cu(II) complexes of Aβ5−9 (A), Aβ5−12 (B), and Aβ5−16 (C) with imidazole (Im) for 1
mM Aβ5−x and 0.8 mM Cu(II) at pH 7.4. The increasing Im concentrations are color-coded from blue to yellow. The directions of changes are
marked by arrows. The titration curves were generated by averaging spectral intensities over the given wavelength ranges for better signal-to-noise
ratios. There were no spectral changes in the d−d range for Aβ5−16.
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3N+1N (Nam, NimHis6, N−+ NIm) complex. The same effects
were observed for titrations of 3N complexes with the excess of
the parent peptide for GHTD-NH2 and GHK
21,38 and Aβ5−9 in
this work. The much less pronounced response of Cu(II)-
Aβ5−16 to Im can be readily explained by the intramolecular 3 +
1N coordination in this complex, employing His13/His14
residues. Nevertheless, a slight change of intensity of the CT
band at 304 nm, along with the absence of changes in d−d
bands can be ascribed to the forced replacement of the
intramolecular ligand by external Im. The conditional stability
constants (KT) for Im binding to Cu(II)-Aβ5−x complexes
were obtained by global fitting of multiple titration curves









where L is the Aβ5−x peptide from the initial binary Cu(II)
complex.
The KT values are provided in Table 4. The strongest ternary
complex was formed for Cu(II)-Aβ5−9 followed by Cu(II)-
Aβ5−12. The lower KT for the latter could be caused by steric
hindrance from additional residues in the Aβ5−12 sequence.
Such effect is evident in the 3-fold lower KT for the second
Aβ5−9 molecule, compared to Im. A further 5-fold lowering of
KT for Cu(II)-Aβ5−16 compared to Cu(II)-Aβ5−12 is apparently
a combination of additional hindrance and the competition
from the intramolecular His13/His14 binding. The compar-
ison of CK values presented in Table 4 indicates that this
interaction increases the overall Cu(II) affinity of Aβ5−16 by 1.8
times. This value is in excellent agreement with that derived
from the 0.33 pH units shift of OH− coordination (Aβ5−9 vs
Aβ5−16, 2.1 times). Therefore, the lowering of Im affinity to
Cu(II)-Aβ5−16 is a combination of competition between Im
and His13/His14 and the increased hampering of Im access to
the Cu(II) binding site.
Additionally, we performed a titration of Cu(II)-Aβ5−9 with
Aβ1−16 (SI, Figure S9). Partial precipitation of the ternary
complex limited the accuracy of the TK7.4 determination, which
was estimated as 5200 M−1 (Table 4). This high stability
compared to other ternary complexes of Cu(II)-Aβ5−x can be
attributed in part to the presence of three His imidazole
ligands in Aβ1−16 available for the binding, and in part to
intermolecular interactions between the Cu(II)-Aβ5−9 pep-
Figure 10. CV (A−F) and DPV (G−I) curves of 0.5 mM Aβ5−9 (A, D, G), Aβ5−12 (B, E, H), and Aβ5−16 (C, F, I) recorded in the absence (dashed
line) or the presence of 0.40 mM Cu(II) and 5.0 mM imidazole, pH 7.4.





OX EDPV IDPV (μA) ECV
OX EDPV IDPV (μA)
Cu(II)-Aβ5−9 −0.579(5) −0.025(1) −0.453(5) −1.318(4) 1.297(2) 1.184(4) 2.77(5)
Cu(II)-Aβ5−9-Im −0.576(1) 0.011(4) −0.492(1) −1.490(7) 1.094(5) 1.024(2) 2.918(9)
Cu(II)-Aβ5−12F −0.633(5) 0.054(3) −0.540(1) −1.473(6) 1.269(5) 1.158(2) 3.02(5)
Cu(II)-Aβ5−12 −0.669(1) −0.062(2) −0.523(2) −1.037(5) 1.159(2) 1.018(2) 0.469(5)
Cu(II)-Aβ5−12-Im −0.647(3) 0.008(3) −0.516(1) −1.000(6) 0.955(4) 0.863(2) 0.145(1)
Cu(II)-Aβ5−16 −0.680(4) 0.200(5) −0.557(2) −0.434(5) 1.058(4) 0.938(3) 0.065(4)
Cu(II)-Aβ5−16-Im −0.688(2) 0.093(2) −0.560(6) −0.383(7) 0.973(1) 0.876(6) 0.052(2)
aE values are given in V vs Ag/AgCl.
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tides. We also attempted the study of the Cu(II)-Aβ5−16 +
Aβ1−16 system, but it was precluded by poor solubility of the
ternary complex and the apparently weak interaction.
Voltammetry. For further characterization of Aβ5−x
peptides, their binary Cu(II) complexes, and ternary
complexes with Im, we performed a series of electrochemical
experiments using cyclic voltammetry (CV) and differential
pulse voltammetry (DPV). The CV results for Aβ5−9, Aβ5−12,
and Aβ5−16 are presented in Figure 10, with auxiliary CV
results for Aβ5−12F provided in Figure S10. All apo-peptides
were electrochemically inactive in the studied range of
potentials (initially scanning from 0.5 V toward the negative
direction, Figure 10A−C, black, blue, green, dashed lines; gray
dashed line in Figure S10A), except for broad peaks observed
at 0.6−0.9 V for Aβ5−12 and Aβ5−16 (Figure 10E−F, H−I, blue
and green dashed lines) assigned to the Tyr10 phenol ring
oxidation to a thermodynamically unstable tyrosyl radical
subsequently converted into orthoquinone.40−42 Aβ5−9 and
Aβ5−12F were redox silent in this range, as expected (Figure
10D, G; Figure S10B).
The 3N Cu(II)-Aβ5−x complexes yielded irreversible
reduction peaks in voltammograms recorded from +0.5 V to
−0.8 V (Figure 10A−C, Figure S11, black, blue, and green
solid lines and Figure S10A, gray solid line, see Table 6 for CV
and DPV-derived potentials). A significant separation between
the cathodic and anodic peaks suggests a slow electron transfer
and/or a reorganization of the complex structure upon Cu(II)
reduction. This can be explained by the incompatibility of the
planar 3N chelate of Aβ5−x peptides with geometrical
preferences of Cu(I) ions, as pointed out previously by
Hureau et al. in their Cu(II)-GHK study.19 The cathodic peak
of Cu(II)-Aβ5−16 had an altered shape, appeared at the most
negative potential, and had the lowest peak current (Figure
10C green solid line, Table 6). These effects are compatible
with the formation of the 3 + 1N coordination structure
supplanted by the His-13/His-14 imidazole nitrogen.
The Cu(II)-Aβ5−x complexes can generate a Cu(II)/Cu(III)
redox couple at potentials around 1 V and higher (Figure
10D−I (black, blue, and green solid lines) and Figure S10B
(solid gray line)). For binary Cu(II)-Aβ5−x complexes with
Tyr-containing peptides, the Cu(II)/Cu(III) redox signal was
preceded by Tyr10 oxidation peaks of decreased intensity and
shifted to more positive potentials relative to apopeptides, in
agreement with the literature.41 The lack of Cu(III)/Cu(II)
reduction peaks in the studied complexes may be attributed to
the catalytic oxidation of peptide ligands via the electro-
generated (highly oxidizing) Cu(III) species according to an
EC (electrochemical-chemical) mechanism. In addition to the
Tyr phenolic ring, His imidazoles in Cu(II)-Aβ5−16 can also be
oxidized by Cu(III) at such potentials, (Eox ∼ 1.25 V for L-
His42 and ∼1.0 V for His in Aβ42/Aβ1643). The use of faster
scan rates (0.5−5 V/s) did not improve the reversibility of the
studied process (data not shown). The EC mechanism explains
the irreversibility of these Cu(II)/Cu(III) couples, in contrast
to the reversible Cu(II)/Cu(III) process in Aβ4−8 and Aβ4−10F
complexes.44 The potentials of Cu(II)/Cu(III) peaks for Aβ5−x
complexes appeared in the following decreasing order: Cu(II)-
Aβ5−16 > Cu(II)-Aβ5−12 > Cu(II)-Aβ5−12F > Cu(II)-Aβ5−9 (see
Table 6 for values). Additionally, the intensity of the oxidation
current increased in the same sequence.
Finally, electrochemical measurements for ternary Im
complexes of Cu(II)-Aβ5−x were done (Figure 10A−I, gray,
orange, and red solid lines). A 12.5-fold Im excess over Cu(II)
excess was used to ensure full saturation of Cu(II) with Im for
Cu(II)-Aβ5−9 and Cu(II)-Aβ5−12 and 50% saturation for
Aβ5−16, according to equilibrium titrations. No significant
changes in the voltammetric signature were noticed in the
range of negative potentials (Figure 10A−C, Figure S11), but
according to CV and DPV curves registered in the 0.2−1.3 V
potential range (Figure 10D−I), the Im addition shifted both
the Cu(II)/Cu(III) and Tyr10 oxidation toward less positive
potentials. This is in accord with the presence of the 3 + 1N
coordination of Cu(II) in the ternary complex, which stabilizes
Cu(III) better.45 The largest shifts in electrochemical
responses occurred for Cu(II)-Aβ5−9-Im and Cu(II)-Aβ5−12-
Im in relation to the binary complexes. In contrast, a weaker
interaction between Cu(II)-Aβ5−16 and imidazole due to the
presence of the autoternary complex resulted in a smaller
change in redox activity of this chelate. Still, the potentials of
formation of Cu(III) species are probably too high to have a
biological relevance.
Cu(II) Exchange and Biological Relevance. The stability
of a complex is a key property in considering its biological
relevance, as biological fluids are teeming with small molecules
and proteins ready to compete for copper. Aβ peptides are
essentially extracellular, and their toxicity is exerted mostly in
synapses. Not much is known quantitatively about the fast-
changing composition of synaptic cleft fluid. Therefore, we are
forced to make educated guesses regarding Cu(II) complex-
ation by Aβ peptides. The Aβ1−x family peptides bind the
Cu(II) ion with log CK7.4 = 10.04 (x = 16) and 10.43 (x =
40).46 Much higher Cu(II) affinities were determined for
Aβ4−x family peptides,
8 log CK7.4 = 13.53 (x = 16),
16 and 14.18
(x = 9).47 The affinities of binary Cu(II)-Aβ5−x peptides are
closer to Cu(II)-Aβ4−x, log
CK7.4 = 12.76 (x = 9), and 12.98 (x
= 16). However, unlike Aβ4−x, the Aβ5−x peptides can elevate
their Cu(II) binding capability via ternary complexes, which is
a feature shared with other Xaa-His peptides.17,20,21,37 Figure
11 presents the evolution of log CK7.4 of ternary Im and Aβ1−16
complexes of Cu(II)-Aβ5−9 and Cu(II)-Aβ5−16 calculated using
the data presented in Tables 1, 2, and 4.
This simulation clearly shows that in the presence of a ∼1
mM amount of external imidazole-bearing ligands Aβ5−9 can
become a stronger Cu(II) chelator than the longer Aβ5−x
species. Furthermore, at ca. 30 mM Im the Cu(II) binding
ability of Aβ5−16 equals that of Aβ4−16, and that of Aβ5−9
Figure 11. Theoretical evolution of log CK7.4 of ternary complexes
Cu(II)-Aβ5−9/Im, Cu(II)-Aβ5−16/Im, and Cu(II)-Aβ5−9/Aβ1−16 cal-
culated using the data presented in Tables 1, 2, and 4.
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matches Aβ4−9. While the actual role of Aβ4−x peptides in brain
copper metabolism remains speculative, we postulate that the
longer species serve to mop up the excess of Cu(II) ions from
the synaptic cleft,18 and Aβ4−9, as product of Aβ4−40 cleavage
by neprilysin may participate in the export of copper across the
blood−brain barrier.48,49 Aβ5−x peptides are normally only very
minor contributors to the overall β-amyloid pool but our
results indicate that these peptides, when multiplicated as a
result of therapeutic intervention, may interfere with the
synaptic and extrasynaptic Cu(II) handling. The affinity of the
Cu(II)-Aβ5−9/Aβ1−16 complex, much higher than that of
imidazole, points at a possibility of strong, specific interactions
with larger ligands that can be recruited from the Aβ family or
other synaptic proteins. Despite the similar overall affinity,
Cu(II)-Xaa-His and Cu(II)-Xaa-Zaa-His (ATCUN) com-
plexes differ in the Cu(II) exchange kinetics, with Cu(II)-
Xaa-His complexes reported as much more labile.50 They
could thus interfere with proper Cu(II) delivery. In particular,
Aβ5−9 which most likely could be generated by neprilysin
analogously to Aβ4−9, could theoretically intercept Cu(II) ions
faster than the ATCUN peptides and release them off target,
e.g. intracellularly, causing oxidative stress in brain cells.49
In order to directly find out how Aβ5−x and Aβ4−x peptides
could compete for Cu(II) ions, we contacted them directly, by
forming the Cu(II)-Aβ5−9 complex at pH 7.4 and then
contacting it with equimolar Aβ4−9. The reaction was then
followed for 24 h, as presented in Figure 12.
By comparing its course with the spectra presented above
and with those published previously by Bossak-Ahmad et al.47
one can clearly see that the process of Cu(II) transfer from
Aβ5−x to Aβ4−x, along the gradient of affinities, is mediated by
the formation of the ternary 3N+NAβ(4−9) complex. Interest-
ingly, however, the overall process, measured at the maximum
of Cu(II)-Aβ4−x absorption, was very slow, taking more than
24 h to complete. Even more interestingly, the reaction had
not one, but two slow steps. The first one, taking the first 2.5 h
of incubation and characterized by an isosbestic point at 621
nm, was apparently the formation of the ternary complex,
which then re-equilibrated into the final 4N Cu(II)-Aβ4−9
species with the isosbestic point at 578 nm. This experiment
shows that the formation of ternary complexes can stabilize the
Cu(II)-Aβ5−x complexes not just thermodynamically, but also
kinetically. Taking into account the milliseconds to seconds to
minutes time scale of chemical processes in the synapses, such
slow equilibrations between Aβ5−x and Aβ4−x indicate that
ternary Cu(II)-Aβ5−x complexes with external ligands,
including other Aβ peptides, may indeed interfere with copper
brain physiology.
Electrochemical properties of Cu(II)-Aβ5−x complexes may
further contribute to the impairment of brain copper
metabolism by enabling the Cu(II)/Cu(I) cycle in the high-
affinity Cu(II) pool, not accessible to much weaker Cu(II)-
Aβ1−x complexes. In this fashion the overproduction of Aβ5−x
peptides could also enhance the oxidative stress and reactive
oxygen species (ROS) generation, normally ascribed to
Cu(II)-Aβ1−x species.
51−53 On the other hand, the oxidation
of Cu(II) ions in Aβ5−x complexes to Cu(III) is even less likely
than in Aβ4−x complexes, but the presence of imidazole shifted
the oxidation potential of the Cu(II)/Cu(III) couple toward
less positive potential values, thus slightly increasing the
probability of this reaction in vivo. Taken together, our results
indicate that Aβ5−x peptides, which bind Cu(II) ions much
more strongly than Aβ1−x peptides
46 and only slightly more
weakly than Aβ4−x peptides,
16,47 could interfere with Cu(II)
handling by these peptides, adding to copper dyshomeostasis
in Alzheimer brains, especially in the presence of auxiliary
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microscopic acid−base parameters from NMR−pH titrations. Anal.
Bioanal. Chem. 2004, 378, 1428−1448.
(32) Daniele, P.; Zerbinati, O.; Zelano, V.; Ostacoli, G.
Thermodynamic and spectroscopic study of copper(II)-glycyl-L-
histidylglycine complexes in aqueous solution. J. Chem. Soc., Dalton
Trans. 1991, 2711−2715.
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(39) Krez̧ėl, A.; Woj́cik, J.; Maciejczyk, M.; Bal, W. May GSH and l-
His contribute to intracellular binding of zinc? Thermodynamic and
solution structural study of a ternary complex. Chem. Commun. 2003,
704−705.
(40) Enache, T. A.; Oliveira-Brett, A. M. Phenol and para-
substituted phenols electrochemical oxidation pathways. J. Electroanal.
Chem. 2011, 655, 9−16.
(41) Suprun, E. V.; Zaryanov, N. V.; Radko, S. P.; Kulikova, A. A.;
Kozin, S. A.; Makarov, A. A.; Archakov, A. I.; Shumyantseva, V. V.
Tyrosine Based Electrochemical Analysis of Amyloid-β Fragment (1−
16) Binding to Metal(II) Ions. Electrochim. Acta 2015, 179, 93−99.
(42) Enache, T. A.; Oliveira-Brett, A. M. Peptide methionine
sulfoxide reductase A (MsrA): direct electrochemical oxidation on
carbon electrodes. Bioelectrochemistry 2013, 89, 11−18.
(43) Suprun, E. V.; Khmeleva, S. A.; Radko, S. P.; Kozin, S. A.;
Archakov, A. I.; Shumyantseva, V. V. Direct electrochemical oxidation
of amyloid-β peptides via tyrosine, histidine, and methionine residues.
Electrochem. Commun. 2016, 65, 53−56.
(44) Wiloch, M. Z.; Wawrzyniak, U. E.; Ufnalska, I.; Bonna, A.; Bal,
W.; Drew, S. C.; Wroblewski, W. Tuning the Redox Properties of
Copper(II) Complexes with Amyloid-Beta Peptides. J. Electrochem.
Soc. 2016, 163 (13), G196−G199.
(45) Ufnalska, I.; Warzyniak, U. E.; Bossak-Ahmad, K.; Bal, W.;
Wrob́lewski, W. Electrochemical studies of binary and ternary
copper(II) complexes with α-factor analogues. J. Electroanal. Chem.
2020, 862, 114003.
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